Andhra CM visits Port City; ordered inquiry in reactor blast
Andhra Pradesh Chief Minister N Kiran Kumar Reddy today visited Port City and expressed 'shock and anguish' over the incident and directed the authorities concerned to conduct an inquiry and submit a report immediately.
The joint chief inspector of factories will conduct the inquiry.
The CM met those who injured in the Reactor blast at ABC Corporte hospital in the Port City, He said the government should take steps to ensure that all safety standards were followed in major industrial units.
There should be regular supervision by the authorities concerned in this regard, he added.
Yesterday. in a reactor explosion at the manufacturing facility of Hetero Drugs at M Narasapuram, 100 km from the port city, two employees were killed and four seriously injured.
The deceased were identified as officers of the unit -- Jayadheer Reddy (35) of Sattupalli in Khammam and Karri Tirupati Rao (30) of Makkuva in Vizianagaram district. Of the four injured persons, condition of the two- Paparao and Venkata Rao -was said to be critical as they suffered more than 70 per cent burn injuries.
They were shifted to a corporate hospital in the Port City.
The other two have been identified as chemist M Naveen of Payakaraopet and office assistant Ch Devullu of S Rayavaram mandal in the district.
Andhra Pradesh Tribal welfare minister P Bala Raju, who visited the hospital along with four state ministers and district collector V Seshadri, confirmed that two employees were killed in the incident and another four severelyinjured.
The Nakkapalli plant, set up in 2007, manufactures bulk drugs.
It has nearly 3,000 employees and also several casual workers taking part in three shift operations. This is the first incident in the factory.
The pharma major manufactures active pharmaceuticals and finished dosages. It has been proposing to expand the unit in Nakkapalli. The company has a pharma special economic zone in Jadcherla, Mahboobnagar, close to Hyderabad.
The company is a major supplier of anti-retrovirals, having won global contracts to supply to different countries. It also has the license from Roche to produce 'Tamiflu', the anti-influenza and swine flu treatment drug.